Do analysts recommend PEPG or CELU?

PepGen currently has a consensus target price of $11.50, suggesting a potential upside of 285.91%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts plainly believe PepGen is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PEPG or CELU more profitable?

PepGen has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Celularity -345.45% N/A -77.94%

Do analysts rate CELU or CHRS?

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 727.07%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend CELU or ABOS?

Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 173.97%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Celularity (CELU) Competitors

$1.41 -0.03 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 +0.03 (+1.91%)

As of 07:56 PM Eastern

Compare

CELU vs. PEPG, CHRS, VYGR, ABOS, and DTIL

Should you buy Celularity stock or one of its competitors? Celularity's main competitors and comparable companies include PepGen (PEPG), Coherus Oncology (CHRS), Voyager Therapeutics (VYGR), Acumen Pharmaceuticals (ABOS), and Precision BioSciences (DTIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celularity compare to PepGen?

PepGen (NASDAQ:PEPG) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

58.0% of PepGen shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PepGen has higher earnings, but lower revenue than Celularity. PepGen is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Celularity	$26.55M	1.54	-$91.72M	-$3.33	N/A

In the previous week, PepGen had 4 more articles in the media than Celularity. MarketBeat recorded 6 mentions for PepGen and 2 mentions for Celularity. PepGen's average media sentiment score of 0.94 beat Celularity's score of 0.44 indicating that PepGen is being referred to more favorably in the media.

Company	Overall Sentiment
PepGen	Positive
Celularity	Neutral

PepGen has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

PepGen currently has a consensus target price of $11.50, suggesting a potential upside of 285.91%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts plainly believe PepGen is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PepGen has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Celularity	-345.45%	N/A	-77.94%

Summary

PepGen beats Celularity on 11 of the 15 factors compared between the two stocks.

How does Celularity compare to Coherus Oncology?

Celularity (NASDAQ:CELU) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Coherus Oncology has a net margin of -259.41% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Coherus Oncology has higher revenue and earnings than Celularity. Coherus Oncology is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.54	-$91.72M	-$3.33	N/A
Coherus Oncology	$42.17M	4.87	$168.02M	-$1.03	N/A

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 727.07%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

19.0% of Celularity shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Celularity had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.78 beat Celularity's score of 0.44 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Neutral
Coherus Oncology	Very Positive

Summary

Coherus Oncology beats Celularity on 12 of the 16 factors compared between the two stocks.

How does Celularity compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Celularity has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$34.46M	5.70	-$119.72M	-$1.80	N/A
Celularity	$26.55M	1.54	-$91.72M	-$3.33	N/A

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Voyager Therapeutics has a net margin of -312.63% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Celularity	-345.45%	N/A	-77.94%

Voyager Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 417.24%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Voyager Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Celularity has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

In the previous week, Voyager Therapeutics and Voyager Therapeutics both had 2 articles in the media. Voyager Therapeutics' average media sentiment score of 0.95 beat Celularity's score of 0.44 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Positive
Celularity	Neutral

Summary

Voyager Therapeutics beats Celularity on 12 of the 16 factors compared between the two stocks.

How does Celularity compare to Acumen Pharmaceuticals?

Celularity (NASDAQ:CELU) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Celularity has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.54	-$91.72M	-$3.33	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 2 mentions for Celularity. Acumen Pharmaceuticals' average media sentiment score of 0.89 beat Celularity's score of 0.44 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Neutral
Acumen Pharmaceuticals	Positive

19.0% of Celularity shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Celularity has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 173.97%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Acumen Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Summary

Acumen Pharmaceuticals beats Celularity on 8 of the 15 factors compared between the two stocks.

How does Celularity compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Precision BioSciences has higher revenue and earnings than Celularity. Precision BioSciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.78	-$45.72M	-$2.80	N/A
Celularity	$26.55M	1.54	-$91.72M	-$3.33	N/A

Precision BioSciences has a net margin of -96.73% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Celularity	-345.45%	N/A	-77.94%

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Precision BioSciences has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Celularity has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Precision BioSciences presently has a consensus price target of $32.25, suggesting a potential upside of 349.79%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Precision BioSciences is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Celularity had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.63 beat Celularity's score of 0.44 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Precision BioSciences	Very Positive
Celularity	Neutral

Summary

Precision BioSciences beats Celularity on 12 of the 16 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.82M	$3.85B	$7.12B	$12.83B
Dividend Yield	N/A	3.63%	2.56%	10.57%
P/E Ratio	-0.42	14.18	273.26	25.18
Price / Sales	1.54	1,408.71	638.34	89.67
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	-1.07	15.12	10.33	6.20
Net Income	-$91.72M	-$22.82M	$3.49B	$358.38M
7 Day Performance	-16.07%	-4.31%	-3.29%	-2.35%
1 Month Performance	101.37%	0.39%	-0.26%	-2.61%
1 Year Performance	-39.48%	38.28%	17.32%	8.08%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	0.3076 of 5 stars	$1.41 -1.7%	N/A	-38.9%	$40.82M	$26.55M	N/A	220	Short Interest Increase
PEPG PepGen	2.7499 of 5 stars	$3.12 +4.3%	$11.50 +268.6%	+115.7%	$216.09M	N/A	N/A	30	News Coverage Positive News Analyst Forecast
CHRS Coherus Oncology	2.1665 of 5 stars	$1.37 +1.5%	$8.67 +532.6%	+2.3%	$211.67M	$42.17M	N/A	330
VYGR Voyager Therapeutics	2.8993 of 5 stars	$3.43 -0.6%	$16.50 +381.0%	-23.3%	$211.36M	$40.37M	N/A	100
ABOS Acumen Pharmaceuticals	2.4997 of 5 stars	$2.92 +2.5%	$8.00 +174.0%	+111.9%	$211.17M	N/A	N/A	20	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. PEPG, CHRS, VYGR, ABOS, and DTIL

How does Celularity compare to PepGen?

Summary

How does Celularity compare to Coherus Oncology?

Summary

How does Celularity compare to Voyager Therapeutics?

Summary

How does Celularity compare to Acumen Pharmaceuticals?

Summary

How does Celularity compare to Precision BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. PEPG, CHRS, VYGR, ABOS, and DTIL

How does Celularity compare to PepGen?

Do institutionals & insiders have more ownership in PEPG or CELU?

Which has preferable earnings & valuation, PEPG or CELU?

Does the media prefer PEPG or CELU?

Which has more volatility and risk, PEPG or CELU?

Do analysts recommend PEPG or CELU?

Is PEPG or CELU more profitable?

Summary

How does Celularity compare to Coherus Oncology?

Which has more risk & volatility, CELU or CHRS?

Is CELU or CHRS more profitable?

Which has better earnings & valuation, CELU or CHRS?

Do analysts rate CELU or CHRS?

Do insiders and institutionals hold more shares of CELU or CHRS?

Does the media refer more to CELU or CHRS?

Summary

How does Celularity compare to Voyager Therapeutics?

Which has better valuation and earnings, VYGR or CELU?

Do institutionals & insiders hold more shares of VYGR or CELU?

Is VYGR or CELU more profitable?

Do analysts recommend VYGR or CELU?

Which has more risk & volatility, VYGR or CELU?

Does the media refer more to VYGR or CELU?

Summary

How does Celularity compare to Acumen Pharmaceuticals?

Which has stronger valuation and earnings, CELU or ABOS?

Does the media favor CELU or ABOS?

Do institutionals and insiders have more ownership in CELU or ABOS?

Which has more volatility & risk, CELU or ABOS?

Do analysts recommend CELU or ABOS?

Is CELU or ABOS more profitable?

Summary

How does Celularity compare to Precision BioSciences?

Which has higher valuation and earnings, DTIL or CELU?

Is DTIL or CELU more profitable?

Do insiders and institutionals hold more shares of DTIL or CELU?

Which has more volatility & risk, DTIL or CELU?

Do analysts prefer DTIL or CELU?

Does the media refer more to DTIL or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools